VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MKL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MKLMarkel Corporation
$1969.34$24.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksMKLFinancials

Markel Corporation (MKL) Financials

30Y historyFree accessUpdated daily

Revenue growth has exhibited extreme cyclicality, swinging from a 31.8% expansion in 2024Q3 to a 26.4% contraction in 2025Q1, culminating in a 2026Q1 operating loss of $273.3 million.

MKL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Revenue16.57B16.59B16.75B15.71B11.81B12.92B9.64B9.52B6.95B6.06B5.61B5.37B5.13B4.32B3B2.63B2.23B2.07B1.98B2.48B2.52B2.2B2.26B2.09B1.77B1.4B1.09B524.32M426M419M366.7M
Revenue Growth %7.74%-0.96%6.6%33.02%-8.55%34.02%1.26%36.98%14.59%8.09%4.48%4.6%18.75%44.1%14.07%18.18%7.54%4.69%-20.4%-1.42%14.49%-2.74%8.13%18.17%26.68%27.68%108.74%23.08%1.67%14.26%6.72%
Medical Costs & Claims6.39B5.08B7.48B7.63B8.41B7.03B6.26B4.67B4.3B4.22B3.25B2.75B2.92B2.34B1.58B1.72B1.37B992.86M1.27B1.85B1.9B1.95B1.98B1.85B1.6B1.5B1.07B440.33M328.18M120.1M0
Medical Cost Ratio %38.56%30.62%44.64%48.57%71.17%54.38%64.91%49.03%61.94%69.56%57.91%51.26%56.88%54.09%52.81%65.52%61.66%47.98%64.2%74.62%75.44%88.64%87.61%88.64%90.48%107.36%97.82%83.98%77.04%28.66%0%
Gross Profit10.18B11.51B9.27B8.08B3.41B5.89B3.38B4.85B2.64B1.85B2.36B2.62B2.21B1.98B1.42B906.79M853.27M1.08B707.56M630.35M618.57M249.84M280.26M237.67M168.48M-102.87M23.86M83.99M97.82M298.9M366.7M
Gross Margin %61.44%69.38%55.36%51.43%28.83%45.62%35.09%50.97%38.06%30.44%42.09%48.74%43.12%45.91%47.19%34.48%38.34%52.02%35.8%25.38%24.56%11.36%12.39%11.36%9.52%-7.36%2.18%16.02%22.96%71.34%100%
Gross Profit Growth %-24.12%14.75%137.29%-42.21%74.25%-30.3%83.46%43.27%-21.83%-9.77%18.26%11.53%40.18%56.13%6.27%-20.73%52.14%12.25%1.9%147.59%-10.86%17.92%41.07%263.78%-531.08%-71.59%-14.14%-67.27%-18.49%6.72%
Operating Expenses7.88B8.78B5.64B5.43B3.56B2.76B2.38B2.57B2.65B1.76B1.73B1.88B1.77B1.62B1.1B716.59M557.76M877.83M867.39M58.4M65.17M63.84M56.22M56.09M50.78M79.33M75.67M30.55M22.44M20.1M8M
OpEx / Revenue %47.55%52.91%33.64%34.54%30.11%21.39%24.71%26.96%38.17%29%30.86%34.92%34.54%37.54%36.79%27.25%25.06%42.42%43.88%2.35%2.59%2.9%2.49%2.68%2.87%5.68%6.91%5.83%5.27%4.8%2.18%
Depreciation & Amortization138.79M0342.36M319.73M309.45M336.39M307.07M269.24M227.85M203.87M194.15M200.99M203.58M190.07M87.33M70.57M53.59M31.17M31.19M30.53M34.04M36.34M31.34M39.26M28.23M41.91M32.4M12.86M7.3M7.3M10.9M
Combined Ratio %86.11%83.53%78.28%83.11%101.28%75.77%89.62%75.99%100.11%98.56%88.77%86.18%91.42%91.63%89.6%92.77%86.72%90.4%108.09%76.97%78.03%91.55%90.1%91.32%93.35%113.04%104.73%89.81%82.3%33.46%2.18%
Operating Income2.3B2.73B3.64B2.65B-151.57M3.13B1B2.29B-7.86M87.3M629.92M742.11M440.38M361.74M312.05M190.2M295.51M198.64M-159.83M571.96M553.4M186M224.04M181.58M117.69M-182.2M-51.81M53.44M75.39M278.8M358.7M
Operating Margin %13.89%16.47%21.72%16.89%-1.28%24.23%10.38%24.01%-0.11%1.44%11.23%13.82%8.58%8.37%10.4%7.23%13.28%9.6%-8.09%23.03%21.97%8.45%9.9%8.68%6.65%-13.04%-4.73%10.19%17.7%66.54%97.82%
Operating Income Growth %--24.88%37.08%1850.86%-104.84%212.84%-56.23%29200.04%-109%-86.14%-15.12%68.52%21.74%15.92%64.07%-35.64%48.77%224.28%-127.94%3.35%197.53%-16.98%23.38%54.29%164.6%-251.69%-196.94%-29.11%-72.96%-22.27%7.04%
EBITDA2.49B2.94B3.98B2.97B157.88M3.47B1.31B2.56B219.99M291.17M824.07M943.09M643.96M551.81M399.38M260.77M349.1M229.81M-128.64M602.49M587.44M222.34M255.38M220.85M145.92M-140.28M-19.41M66.3M82.68M286.1M369.6M
EBITDA Margin %15.03%17.71%23.76%18.92%1.34%26.83%13.56%26.84%3.17%4.8%14.69%17.56%12.54%12.76%13.31%9.92%15.69%11.11%-6.51%24.26%23.32%10.11%11.29%10.56%8.24%-10.04%-1.77%12.64%19.41%68.28%100.79%
Interest Expense204.66M205.91M204.3M185.08M196.06M183.58M177.58M171.69M154.21M132.45M129.9M118.3M117.44M114M92.76M86.25M73.66M53.97M48.21M56.25M65.17M63.84M56.22M51.96M40.1M48.65M52.35M25.15M20.41M20.1M8M
Non-Operating Income-153.77M-205.91M-204.3M-185.08M-196.06M-183.58M-177.58M-171.69M-154.21M-132.45M-129.9M-118.3M-117.44M-114M-92.76M-86.25M-73.66M-53.97M-48.21M-56.25M-65.17M-63.84M-56.22M-51.96M-40.1M-48.65M-52.35M-25.15M-20.41M258.7M350.7M
Pretax Income2.31B2.73B3.64B2.65B-151.57M3.13B1B2.29B-7.86M87.3M629.92M742.11M440.38M361.74M312.05M190.2M295.51M198.64M-159.83M571.96M553.4M186M224.04M181.58M117.69M-182.2M-51.81M53.44M75.39M66.3M37M
Pretax Margin %13.91%16.47%21.72%16.89%-1.28%24.23%10.38%24.01%-0.11%1.44%11.23%13.82%8.58%8.37%10.4%7.23%13.28%9.6%-8.09%23.03%21.97%8.45%9.9%8.68%6.65%-13.04%-4.73%10.19%17.7%15.82%10.09%
Income Tax486.32M580.3M790.29M552.62M-48.21M683.96M168.68M486.35M122.5M-313.46M169.48M152.96M116.69M77.9M53.8M41.71M27.78M-3.78M-101.39M166.29M160.9M38.09M58.63M58.11M42.37M-56.48M-24.21M12.83M18.09M15.9M-9.7M
Effective Tax Rate %21.1%21.24%21.73%20.82%31.81%21.85%16.86%21.28%-1559.49%-359.08%26.9%20.61%26.5%21.53%17.24%21.93%9.4%-1.9%63.44%29.07%29.07%20.48%26.17%32%36%31%46.74%24%24%23.98%-26.22%
Net Income1.77B2.11B2.75B2B-216.28M2.42B816.03M1.79B-128.18M395.27M455.69M582.77M321.18M281.02M253.38M142.03M266.79M201.64M-58.77M405.67M392.5M147.91M165.41M123.48M75.32M-125.72M-27.59M40.61M57.29M50.4M46.7M
Net Margin %10.7%12.7%16.4%12.7%-1.83%18.76%8.47%18.81%-1.84%6.52%8.12%10.85%6.26%6.5%8.45%5.4%11.99%9.74%-2.97%16.34%15.58%6.72%7.31%5.9%4.26%-9%-2.52%7.75%13.45%12.03%12.74%
Net Income Growth %-3.83%-23.3%37.62%1022.92%-108.93%196.94%-54.42%1496.84%-132.43%-13.26%-21.81%81.45%14.29%10.91%78.41%-46.77%32.31%443.11%-114.49%3.35%165.36%-10.58%33.96%63.93%159.92%-355.63%-167.94%-29.11%13.68%7.92%35.36%
EPS (Diluted)157.85169.22199.32146.98-23.72176.5155.63129.07-9.2125.8131.2741.7422.2722.4825.8914.6027.2720.52-5.9940.6439.4014.8016.4112.317.65-14.73-3.997.2010.178.928.30
EPS Growth %2.27%-15.1%35.61%719.65%-113.44%217.29%-56.9%1501.41%-135.68%-17.46%-25.08%87.43%-0.93%-13.17%77.33%-46.46%32.89%442.57%-114.74%3.15%166.22%-9.81%33.31%60.91%151.93%-269.17%-155.42%-29.2%14.01%7.47%34.96%
EPS (Basic)-169.74199.69147.32-23.72176.9255.67129.25-9.2125.8931.4141.9922.3822.5725.9614.6627.3120.54-5.9940.7340.4315.0516.7912.557.67-14.73-3.997.2710.419.208.58
Diluted Shares Outstanding11.23M12.73M13.04M13.38M13.58M13.8M13.82M13.88M13.92M14.01M14.08M14.06M14.06M12.59M9.76M9.73M9.78M9.83M9.81M9.98M9.96M9.99M10.08M10.03M9.85M8.53M6.92M5.64M5.63M5.65M5.63M

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Underwriting volatility and social inflation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Underwriting Profitability Faces Cyclical Headwinds

As reported in recent financial statements, Markel's combined ratio deteriorated to 107.7% in 2026Q1, marking a significant departure from the sub-100% underwriting profitability observed in previous periods, which warrants close investor scrutiny regarding the sustainability of the firm's core insurance engine during periods of heightened loss activity.

The sharp spike in the combined ratio suggests that the company is currently failing to generate an underwriting profit, forcing a reliance on investment income or Ventures' cash flow to offset insurance losses. This volatility appears to be driven by inconsistent loss ratios, which have fluctuated significantly over the last ten quarters, indicating that the firm's specialty lines may be experiencing greater-than-anticipated claims pressure.

Revenue Growth Exhibits Erratic Cyclicality

Based on the provided quarterly data, Markel's revenue growth has displayed extreme volatility, swinging from a 31.8% expansion in 2024Q3 to a 26.4% contraction in 2025Q1, suggesting that the company's top-line trajectory is highly sensitive to both insurance market cycles and the performance of its non-insurance Ventures segment.

The inconsistency in revenue growth implies that the firm's strategy of balancing insurance premiums with Ventures' transactional business may be creating a lumpy earnings profile. Investors should monitor whether this lack of top-line stability reflects a deliberate choice to prioritize underwriting discipline over volume or if it indicates a weakening competitive position in key specialty markets.

2026Q1 Signals Potential Structural Inflection

According to the most recent quarterly figures, the company reported an operating loss of $273.3 million in 2026Q1, a stark reversal from the $734.2 million operating profit seen in 2025Q4, which may indicate that the firm is entering a more challenging phase of its underwriting and operational cycle.

This sudden shift into negative operating territory suggests that the company's diversified model is currently struggling to absorb the combined impact of insurance losses and potential headwinds in its non-insurance businesses. This inflection point warrants further investigation into whether this is a temporary anomaly or the beginning of a more persistent trend of margin compression.

Social Inflation Risks Masking Underlying Weakness

While Markel's historical model relies on the 'three-engine' architecture, the recent surge in loss ratios suggests that persistent social inflation in US casualty lines may be creating a structural drag on earnings that is not fully captured by current pricing strategies or historical reserve assumptions.

The reliance on favorable prior-year development to bolster current-year results may be reaching a limit, as evidenced by the recent deterioration in the combined ratio. If the company is forced to strengthen reserves significantly, it could lead to further earnings volatility that would challenge the market's perception of the firm's underwriting discipline.

MKL — Frequently Asked Questions

Quick answers to the most common questions about buying MKL stock.

What was Markel Corporation's (MKL) revenue in 2025?

For fiscal year 2025, Markel Corporation (MKL) reported total revenue of $16.59B. This represents a 4423.9% increase compared to $366.7M in 1996.

Is Markel Corporation (MKL) profitable?

Markel Corporation (MKL) is profitable, generating $2.11B in net income for the fiscal year ending 2025 with a net profit margin of 12.7%.

What is Markel Corporation's operating profit margin?

Markel Corporation (MKL) reported an operating income of $2.73B, resulting in an operating profit margin of 16.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Markel Corporation's gross profit and gross margin?

Markel Corporation (MKL) generated $11.51B in gross profit for the year, representing a gross profit margin of 69.4%. This demonstrates the company's core pricing power and production efficiency.